Topical Botox Rights Acquired by Allergan

Earlier this year, Allergan announced its acquisition of Anterios, Inc., a clinical stage biopharmaceutical company developing a topical Botox. With the acquisition comes the worldwide rights to ANT-1207, a topical formulation of botulinum toxin, which is being developed for the treatment of crow’s feet lines, acne, and hyperhidrosis (excessive sweating). “The acquisition of Anterios bolsters …

Topical Botox Rights Acquired by Allergan Read More »